No Prescription |
 |
 | ||
|
Xylocaine Generic Lidocaine |
|
| ||
No Prescription » Prescription Drugs 17 » Xylocaine Generic Lidocaine This medicine contains the active ingredient lidocaine hydrochloride (previously known as lignocaine hydrochloride in the UK) which is a type of medicine called a local anaesthetic. Lidocaine acts to block temporarily the pathway of pain impulses along nerve fibres. This relieves or prevents pain in the area where it has been sprayed.What is it used for?Numbing a localised area (local anaesthesia) Buy Xylocaine Generic Lidocaine and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Xylocaine Generic Lidocaine: Product Type: Prescription Drugs 17 Xylocaine ( Generic Lidocaine ) Xylocaine (Generic Lidocaine) Generic Lidocaine 10% Pump Spray Generic Lidocaine Xylocaine
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
